This session brings together senior in-house patent litigators involved in some of the most influential recent pharma and biotech cases, to examine how life sciences litigation strategy is shifting and what in-house teams should be preparing for next.
- Review key cases and court decisions from the past year, and what they reveal about where pharma and biotech patent litigation is evolving.
- How PTAB procedural developments are changing risk assessment, sequencing, and settlement strategy.
- Review venue selection within the US and consider when long-arm litigation can create leverage.

Jason Murata

Petra Scamborova

Rob Rodrigues









